SANUWAVE Health, Inc. (OTCMKTS:SNWV) Climbs Above 10 Cents Per Share

[[tagnumber 0]][[tagnumber 1]]Medical companies in the OTC markets usually get some decent attention even if they are far from generating revenues. They usually have some of the biggest market caps in the marketplace, but that is not the case of SANUWAVE Health, Inc. (OTCMKTS:SNWV).[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]The ticker had its ups and downs since the start of the year. It was swaying around the 15 cent per share mark through April and seemed to show more stability. That, however, was until the company filed its financial report for the first quarter of the year which contained the following numbers in its balance sheet.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 9]] [[tagnumber 10]]cash: $2.45 million[[tagnumber 11]] [[tagnumber 10]]current assets: $2.93 million[[tagnumber 11]] [[tagnumber 10]]current liabilities: $6.18 million[[tagnumber 11]] [[tagnumber 10]]quarterly revenues: $210 thousand[[tagnumber 11]] [[tagnumber 10]]quarterly net loss: $1.15 million[[tagnumber 11]] [[tagnumber 20]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]We can’t argue that these are some decent numbers, especially the fact that the company is generating revenues. Furthermore, we see that the company has managed to significantly cut general and administrative expenses, which is one of the reasons for which the net loss is 55% lower compared to the same period last year.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Still, the company lost nearly half of its value in the session following the filing of the report. What was the reason for this, however? The most probable reason was that the report was itself a reminder of the upcoming maturity date of the $5.3 million HealthTronics notes that was due August 2015.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]The stock managed to somewhat stabilize after the serious blow that it suffered, but things weren’t looking bright. That was, however, until [[tagnumber 32]]SNWV[[tagnumber 33]] announced that they have extended the notes’ maturity date to January 31, 2017. That announcement was made on June 18 and the 8–K filing was accepted by the SEC by the end of the session.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]We saw [[tagnumber 32]]SNWV[[tagnumber 33]] surge in the next day. The company stock finished the week with a 34.12% gain, at a price of $0.114. Trading was not as intense as when the ticker plummeted in the beginning of May and the 886 thousand shares that were traded generated only $93 thousand in daily dollar volume.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]The market cap of $7.1 million that [[tagnumber 32]]SNWV[[tagnumber 33]] commands seems rather small compared to other medical companies traded at the OTC markets, so there is the possibility for the ticker to climb further. Still, nothing is for certain, so doing your due diligence and weighing out the risks before putting any money on the line is crucial.[[tagnumber 2]]